Enzo Biochem (NYSE:ENZ) Now Covered by StockNews.com

StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ) in a report released on Friday. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Price Performance

NYSE:ENZ opened at $0.68 on Friday. Enzo Biochem has a 1 year low of $0.68 and a 1 year high of $1.44. The stock has a 50-day moving average price of $0.93 and a two-hundred day moving average price of $1.05.

Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings data on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative net margin of 81.73% and a negative return on equity of 11.84%.

Enzo Biochem Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 15th were given a $0.10 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.40 annualized dividend and a yield of 58.81%.

Hedge Funds Weigh In On Enzo Biochem

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of Enzo Biochem by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after acquiring an additional 11,742 shares in the last quarter. BBR Partners LLC bought a new stake in shares of Enzo Biochem in the third quarter worth $112,000. XTX Topco Ltd boosted its holdings in Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after purchasing an additional 13,735 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after purchasing an additional 64,417 shares in the last quarter. Institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.